Astellas Institute for Regenerative Medicine et al v. ImStem Biotechnology, Inc. et al

  1. September 05, 2025

    Conn. Biotech Hits Ch. 11 With $2.7M Debt After Patent Suit

    A Connecticut biotech company has filed a voluntary Chapter 11 petition claiming at least $2.7 million in liabilities, mostly debts to Quinn Emanuel Urquhart & Sullivan LLP and Verrill Dana LLP, after both law firms represented it in a since-settled Massachusetts stem cell patent lawsuit.

  2. May 11, 2023

    Astellas, Scientists Settle Stem Cell Patent Inventorship Fight

    Two former University of Connecticut scientists have agreed to remove their names from two embryonic stem cell research method patents to resolve the Astellas Institute for Regenerative Medicine's yearslong litigation challenging their inventorship claims, according to documents filed in Massachusetts federal court.

  3. March 11, 2022

    Astellas Can't Cut Scientists From Stem Cell Patent Apps

    A Massachusetts federal judge cited a lack of evidence for Astellas Institute for Regenerative Medicine to boot two former University of Connecticut scientists from patent applications that are related to an embryonic stem cell research method patent it successfully got the scientists cut from last year.

  4. February 06, 2021

    Astellas Gets Scientists Cut From Stem Cell Patent After Trial

    In a post-trial opinion Friday, a Massachusetts federal judge removed two former University of Connecticut scientists from a patent for an embryonic stem cell research method, ruling that they did not make inventive contributions, handing the win to Astellas Institute for Regenerative Medicine.